Stock Market Today, July: UiPath Gains on Agentic Automation
UiPath edges higher as investors monitor its agentic automation strategy ahead of earnings. This analysis breaks down...
Which Is Better Cash Back Or Points For Travel
Choosing between cash back and points for travel can impact your rewards. Explore which option suits your travel style!
27,012 articles
The Dividend Growth Path That Expands Your Paycheck
Investors chasing steady, rising income can use a dividend-focused playbook to grow a $35,000 annual paycheck over ti...
Quantumscape Stock Soar Today? What Drove the Move
Investors are buzzing about QuantumScape after news of a major automaker collaboration. This article breaks down what...
Should Zeta Global Stock Be Chosen Over AppLovin Stock?
If you're weighing two ad-tech stocks, this guide breaks down how to think about should zeta global stock versus AppL...
Foreign Holders of U.S. Debt May Bring Cash Home Soon
Top foreign owners of U.S. debt are signaling a possible shift toward domestic allocations, a move that could squeeze...
Synopsys Stock Will Year: Analysts Eye Year-End Target
As Synopsys reports strong Q2 results, investors weigh AI-driven catalysts against a heavy debt load and amortization...
2026 Value-Add Real Estate Playbook: 30%–50% ROI Guide
Discover a practical blueprint for 2026 value-add real estate that combines smart deal selection, disciplined financi...
Dyadic (DYAI) 2025 Earnings: Key Takeaways for Investors
As Dyadic gears up to report dyadic (dyai) 2025 earnings, investors should focus on revenue mix, cash runway, and par...
Emerging Market Small Caps Pay Wild Dividends, Outperform
Emerging market small caps are posting growing trailing dividends despite volatile quarterly payments, helping them b...
Amentum (AMTM) 2026 Earnings Outlook: Q2 Deep Dive
Amentum faces a pivotal Q2 2026 earnings season. This deep dive breaks down backlog, margins, and guidance, with prac...
Dividend Stocks Hold Next: 2 Picks for a 20-Year Horizon
Long-term investing isn’t about chasing the hottest trend. It’s about finding durable brands that can pay and grow di...
CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status